Clinical Trials Logo

Clinical Trial Summary

Main objective : Assessing the effect of epoetin beta on Hb rate and the glomerular filtration rate estimated 30 days after kidney transplant.


Clinical Trial Description

French study, prospective, multicenter, open, randomized into two parallel groups:

Group A: NeoRecormon ® 30000 UI: 4 injections Group B: control group without administration of the medical product

Period of recruitment: 18 months Duration of participation of each patient: 90 days Total duration of the test: 21 months.

Main objective : Assessing the effect of epoetin beta on the glomerular filtration rate estimated 30 days after kidney transplant.

Secondary objectives:

Comparing the 2 groups at all times J0 to J90:

- The evolution of renal function

- The survival of patients and grafts

- The time of onset and incidence of acute rejection proved by biopsy

- The correction of anemia

- The need for transfusions

- The need for EPO

- Quality of Life

- The safety processing ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00815867
Study type Interventional
Source Centre Hospitalier Universitaire, Amiens
Contact
Status Completed
Phase Phase 3
Start date October 2007
Completion date September 2009

See also
  Status Clinical Trial Phase
Completed NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Phase 1
Completed NCT02546037 - Clotting With Different Dialyzer Membranes
Recruiting NCT02545920 - To Assess Ear Blood Flow During Dialysis
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A
Completed NCT01158742 - Live Kidney Donor Study -Renal Function Study N/A
Completed NCT00986947 - Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates Phase 2
Completed NCT00765661 - Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients Phase 2
Withdrawn NCT00807274 - Renal Function in Adults With Congenital Heart Disease. N/A
Completed NCT00369382 - Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients Phase 4
Completed NCT00183248 - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients Phase 1/Phase 2
Enrolling by invitation NCT05324878 - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Completed NCT05272800 - BIS-guided Fluid Management in HD Patients N/A
Completed NCT03836508 - Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis N/A
Completed NCT01756508 - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury Phase 2
Completed NCT03723668 - Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
Recruiting NCT04277377 - Nanoparticle for DSA Removal
Terminated NCT00450333 - Dynepo Infrequent Dosing Study Phase 3
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Recruiting NCT04714853 - Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins